Board

▼ Reasons for appointment

Isao Teshirogi became Representative Director and President in 2008. He has actively pushed forward with global research and development and expansion of global business to achieve the Third Medium-Term Business Plan and secured a medium- to long-term profit foundation. After achieving the quantitative targets of “Shionogi Growth Strategy 2020 (SGS2020),” formulated in FY2014, he updated the quantitative targets in October 2016 and also achieved these targets ahead of schedule. In 2020, he started a new Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030),” that includes the Company’s vision toward 2030, “Building Innovation Platforms to Shape the Future of Healthcare.” As the path toward realizing the 2030 Vision has become clearer due to the plan’s initiatives, he re-established the plan in June 2023 as the “STS2030 Revision” and has vigorously moved forward the business transformation, including globalization and business models, with the aim of achieving further growth. 

Attended all 13 Board of Directors meetings of FY2024.

▼ Reasons for appointment

John Keller has served as President and CEO of Shionogi Inc., a U.S. subsidiary of the Company, as well as Senior Vice President of the Global  Business Division and Senior Vice President of the Corporate Strategy Division of the Company, and has been supervising R&D in general as Senior Vice President of the R&D Supervisory Unit since July 2022. With the aim of achieving our Medium-Term Business Plan, which was re-established as “Shionogi Transformation Strategy 2030 (STS2030) Revision” in June 2023, he has developed numerous pipelines and created new development candidates, as well as engaged in partnerships and licensing activities with research institutions and companies around the world and M&As. 

▼ Reasons for appointment

Keiichi Ando has practical experience as a corporate executive at a financial institution and broad insight on finance. He also coordinated the extremely difficult adjustments between the national government and the governments of Osaka Prefecture and Osaka City for the airport management business of Kansai, which was then at a crossroads, and his experience and insight built the foundation of Kansai Airports, which plays a leading role in the current Kansai economy. At the Company’s Board of Directors meetings, he presents many questions and opinions and provides sound advice from the perspective of budget planning and management, capital policies, including investments, and risk management to the ensure effective use of important management resources, while, as chair of the Board, taking into account the timeliness and appropriateness of the proposals. Thus, he recognizes the corporate responsibility we should fulfill and makes management decisions with an emphasis on objectivity and impartiality, without bias in favor of corporate executives or specific interested parties. 

Attended all 13 Board of Directors meetings of FY2024.

▼ Reasons for appointment

Hiroshi Ozaki has abundant practical experience and wide-ranging knowledge in corporate management and organizational management as a manager of a company based in Kansai. He is also the former chairman of the Osaka Chamber of Commerce and Industry, and during his tenure promoted the economic growth of Osaka and Kansai based on the medium-term plan he developed, as well as focusing on promoting the life science industry. At the Company’s Board of Directors meetings, he raises many pertinent questions and provides sound advice on business development, including new business investments and business alliances, and risk management, including IT. Accordingly, he makes management decisions with an emphasis on objectivity and neutrality based on his extensive experience and knowledge. 

Attended all 13 Board of Directors meetings of FY2024.

▼ Reasons for appointment

Takaoki Fujiwara has extensive practical experience and a wide range of knowledge as a manager of a group of companies engaged in urban transport, real estate and entertainment, mainly in the Kansai area. At the Company’s Board of Directors meetings, he provides sound advice, mainly on human resource management, compliance and risk management. Accordingly, he makes decisions that emphasize objectivity and neutrality based on his extensive experience and knowledge.

Attended all 13 Board of Directors meetings of FY2024.

▼ Reasons for appointment

Kyoko Hirose has abundant practical experience as a manager of a company that manufactures and sells key components of industrial sewing machines on a global scale. She also serves as Vice-Chair of the Osaka Chamber of Commerce and Industry and has wide-ranging knowledge as an economic expert, including in the areas of women’s empowerment and diversity. Accordingly, we expect that she will make management decisions with an emphasis on objectivity and neutrality based on her extensive experience and knowledge. 

▼ Reasons for appointment

Noriyuki Kishida has served as the head of administrative units, including the Corporate Communications Office, the Human Resources Department and the Administration Division, and is well-versed in corporate management and corporate governance. He has extensive experience and a wide range of knowledge in corporate management in general, including management strategies, through his track record in promoting internal reforms based on the management infrastructure strategy of the Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030)” as Senior Vice President of the Corporate Supervisory Unit. Accordingly, we judge that he has the appropriate character and insight to perform the duties of a Director who is an Audit and Supervisory Committee Member.

Attended all 11 Board of Directors meetings of FY2024.

Attended all  9 Board of Corporate Auditors meetings of FY2024.

▼ Reasons for appointment

Koji Hanasaki has served as the head of the Pharmaceutical Research Division, the Corporate Strategy Division and the Global Business Division, and is well-versed in R&D, corporate management and overseas businesses. He has extensive experience and a wide range of knowledge in management in general through his track record in supervising supply chain management, including the manufacturing and stable supply of pharmaceuticals, as Senior Vice President of the Supply Supervisory Unit. Accordingly, we judge that he has the appropriate character and insight to perform the duties of a Director who is an Audit and Supervisory Committee Member.

▼ Reasons for appointment

Shuichi Okuhara has extensive experience and a wide range of knowledge as a manager of a venture capital firm in a social environment that places importance on innovation through peer or cross-industrial partnerships. He also has professional expertise in finance and accounting as a certified public accountant and carries out audits suitable for the continually changing business environment. At the Board of Directors and Board of Auditors meetings, he provides sound advice, mainly on the healthcare industry in general, including investments and digital technologies. Accordingly, we expect that he will reflect the appropriateness of Directors’ management decisions and their execution of duties in the Company’s audits from an independent standpoint as an Outside Director.

Attended all 13 Board of Directors meetings of FY2024.

Attended all 11 Board of Corporate Auditors meetings of FY2024.

▼ Reasons for appointment

Fumi Takatsuki has extensive experience and professional insight from her position as an attorney in international corporate law and in legal response relating to the Chinese life science and healthcare industry. Although she has not been involved in company management in any capacity other than as an outside director in the past, at the Company’s Board of Directors meetings, she presents questions particularly concerning business expansion in Asia, including China, from an international corporate legal perspective, as well as providing sound advice on compliance. She makes fair management decisions from a global perspective, giving priority to legal compliance and social norms. Accordingly, we expect that she will reflect the appropriateness of Directors’ management decisions and their execution of duties in the Company’s audits from an independent standpoint as an Outside Director.

Attended all 13 Board of Directors meetings of FY2024.

▼ Reasons for appointment

Yoriko Goto has professional expertise in finance and accounting as a certified public accountant and extensive management experience and broad insight through her service as Chairperson of the Board of Deloitte Tohmatsu Group and Deloitte Touche Tohmatsu LLC, among others. She also audits the Company from a financial, accounting and management perspective, and provides sound advice at the meetings of Board of Directors and Board of Auditors, mainly regarding overseas business development, M&A, fund management and compliance. Accordingly, we expect that she will reflect the appropriateness of Directors’ management decisions and their execution of duties in the Company’s audits from an independent standpoint as an Outside Director.

Attended all 13 Board of Directors meetings of FY2024.

Attended all 11 Board of Corporate Auditors meetings of FY2024.